

---

# Texas Medicaid Vendor Drug Program Drug Utilization Review Board Meeting - Retrospective Drug Use Proposals

Justin Ray Pedigo, PharmD, BCPS

---

FRIDAY, JANUARY 20, 2023

[HTTP://WWW.TXVENDORDRUG.COM/](http://www.txvendordrug.com/)

# Revised Criteria

---

1. Angiotensin-Converting Enzyme Inhibitors
2. Angiotensin II Receptor Blockers
3. Platelet Aggregation Inhibitors
4. Proton Pump Inhibitors
5. Sedative/Hypnotics
6. Serotonin 5-HT<sub>1B</sub>/1D Receptor Antagonists

---

# Revised Criteria: Angiotensin-Converting Enzyme Inhibitors

---

# Angiotensin-Converting Enzyme Inhibitors

---

## Dosage

### *Adults*

- Table 1. ACE Inhibitors as Monotherapy- Maximum Daily Adult Dosage
  - Updated order of table columns to Drug Name, Dosage Form/ Strength, Treatment Indication, Maximum Recommended Dosage
  - Updated captopril dosing for diabetic nephropathy/ proteinuria
  - Removed brand name Monopril<sup>®</sup> (fosinopril), Prinivil<sup>®</sup> (lisinopril), and Aceon<sup>®</sup> (perindopril), only generic formulations currently available

# Angiotensin-Converting Enzyme Inhibitors

---

## Dosage

### *Adults (continued)*

- Table 2. Adult Maximum Dosage Recommendations for ACE Inhibitor Combination Therapy in Hypertension Management
  - Updated available brand & generic availability of amlodipine/ benazepril
  - Removed captopril/ hydrochlorothiazide and brand name Tarka<sup>®</sup> (trandolapril/ verapamil) as product is not currently manufactured

## References

- Reviewed and updated throughout the criteria set

---

# Revised Criteria: Angiotensin II Receptor Blockers

---

# Angiotensin II Receptor Blockers

---

## Dosage

### *Adults*

- Table 1. Maximum Daily Adult Dosages for Angiotensin II Receptor Blockers– Monotherapy
  - Updated order of table columns to Drug Name, Dosage Form/ Strength, Treatment Indication, Maximum Recommended Dosage
  - Removed Teveten<sup>®</sup> (eprosartan) due to product discontinuation
  - Added valsartan oral solution
    - Clarified that valsartan oral solution is not therapeutically equivalent to tablet formulations

# Angiotensin II Receptor Blockers

---

## Dosage

### *Adults*

- Table 2. Maximum Daily Adult Dosages for Angiotensin II Receptor Blockers– Combination Therapy
  - Updated order of table columns to Drug Name, Dosage Form/ Strength, Treatment Indication, Maximum Recommended Dosage
  - Removed Teveten HCT<sup>®</sup> (eprosartan/ hydrochlorothiazide) due to product discontinuation
  - Removed brand name Twynsta<sup>®</sup> (telmisartan/ amlodipine) due to discontinuation



# Angiotensin II Receptor Blockers

---

## Dosage

### *Pediatrics*

- Provided information about pediatric valsartan approval for patients 1-5 years of age
- Added information about valsartan oral solution being approved for patients 6 years of age and older
- Added Entresto® (sacubitril/ valsartan) is approved for symptomatic treatment of heart failure with left ventricular systolic dysfunction in patients 1 year of age and older

# Angiotensin II Receptor Blockers

---

## **Dosage**

### *Pediatrics*

- Table 3. Pediatric Maximum Daily Angiotensin II Receptor Blocker Dosages for Hypertension– Monotherapy
  - Updated dosing for patients 20- < 35 kg
  - Updated valsartan dosing
  - Added valsartan oral solution
- Added Table 4. Pediatric Maximum Daily Angiotensin II Receptor Blocker Dosages for Heart Failure– Combination Therapy
  - Added Entresto® (sacubitril/ valsartan)

## **References**

- Reviewed and updated throughout the criteria set

---

# Revised Criteria: Platelet Aggregation Inhibitors

---

# Platelet Aggregation Inhibitors

---

## Dosage

### *Adults*

- Table 1. Maximum Daily Adult Dosages for PAIs – Monotherapy
  - Removed Durlaza<sup>®</sup> (aspirin) due to product discontinuation
- Table 2. Maximum Daily Adult Dosages for PAIs – Combination Therapy
  - Removed brand name Aggrenox<sup>®</sup> (aspirin/ dipyridamole) due to discontinuation, generic formulations are available
- Table 3. PAI Recommended Treatment Duration (Adults)- Monotherapy
  - Removed Durlaza<sup>®</sup> (aspirin) due to product discontinuation

## References

- Reviewed and updated throughout the criteria set

---

# Revised Criteria: Proton Pump Inhibitors

---

# Proton Pump Inhibitors

---

Updated column order within tables to: Drug Name, Dosage Form/ Strength, Treatment Indication, Maximum Recommended Dosage

## Dosage

### *Adults*

- Table 1. Adult Maximum Daily Acute Doses for Proton Pump Inhibitors- Monotherapy
  - Updated *Helicobacter pylori* dosing for esomeprazole magnesium to reflect product labeling
  - Added asterisk for therapies with guideline recommended dosage that varies from product labeling. Added recommendation to bottom of table
  - Removed omeprazole 2 mg/mL oral suspension. This is currently a compounded product

# Proton Pump Inhibitors

---

## Dosage

### *Adults (continued)*

- Table 2. Adult Maximum Daily Acute Doses for Proton Pump Inhibitors- Combination Therapy
  - Updated Zegerid® (omeprazole/ sodium bicarbonate) dosing to reflect product labeling
- Table 3. Adult Maximum Daily Maintenance Dose for Proton Pump Inhibitors- Monotherapy
  - Removed omeprazole 2 mg/ mL oral suspension
- Table 4. Adult Maximum Daily Maintenance Dose for Proton Pump Inhibitors – Combination Therapy
  - Added that generic formulations of Vimovo® (esomeprazole/ naproxen) are available

# Proton Pump Inhibitors

---

## Dosage

### *Pediatrics*

- Updated dexlansoprazole indication to include erosive esophagitis maintenance therapy in pediatric patients 12-17 years of age
- Table 5. Pediatric Maximum Daily Acute Doses for Proton Pump Inhibitors – Monotherapy
  - Updated lansoprazole formatting for ages and weights for consistency
- Table 6. Pediatric Maximum Daily Maintenance Doses for Proton Pump Inhibitors – Monotherapy
  - Added omeprazole magnesium
- Table 7. Pediatric Maximum Daily Maintenance Doses for Proton Pump Inhibitors – Combination Therapy
  - Added that generic formulations of Vimovo<sup>®</sup> (esomeprazole/ naproxen) are available



# Proton Pump Inhibitors

---

## Dosage

- Table 8. ESPGHAN/NASPGHAN Pediatric *H. pylori* Treatment Recommendations
  - Added PPI dosing to treatment option 3
  - Added alternate antibiotic recommendation for patients greater than 8 years of age with resistant *H. pylori* or allergy to amoxicillin

## Duration of Therapy

- Table 11. PPI Acute Duration of Therapy for Pediatric Patients – Monotherapy
  - Updated treatment duration for omeprazole and omeprazole magnesium
  - Updated information about prevention and treatment duration of lansoprazole for NSAID-associated gastric ulcer

# Proton Pump Inhibitors

---

## **Drug-Drug Interactions**

- Reviewed and updated using Micromedex, Clinical Pharmacology, and product labeling

## **References**

- Reviewed and updated throughout the criteria set

---

# Revised Criteria: Sedative/Hypnotics

---

# Sedative/Hypnotics

---

## Dosage

### *Adults*

- Table 1. Maximum Recommended Daily Dosages for Sedative/Hypnotics in Adults: Benzodiazepines
  - Added that generic formulation of quazepam is available
- Table 2. Maximum Recommended Daily Dosages for Sedative/Hypnotics in Adults: Barbiturates
  - Updated maximum dosing of phenobarbital to reflect updated product labeling
  - Removed secobarbital due to product discontinuation

# Sedative/Hypnotics

---

## Dosage

### *Adults (Continued)*

- Table 3. Maximum Recommended Daily Dosages for Sedative/Hypnotics in Adults: Non-Benzodiazepine, Benzodiazepine Receptor Agonists
  - Added that generic formulations of eszopiclone are available
  - Removed Intermezzo<sup>®</sup> (zolpidem sublingual tablets) due to product discontinuation
- Table 4. Maximum Recommended Daily Dosages for Sedative/Hypnotics in Adults: Melatonin Receptor Agonists
  - Added generic formulations for ramelteon

# Sedative/Hypnotics

---

## Dosage

### *Adults (Continued)*

- Table 5. Maximum Recommended Daily Dosages for Sedative/Hypnotics in Adults: Orexin Receptor Antagonists
  - Added Quviviq® (daridorexant)
- Table 6. Maximum Recommended Daily Dosages for Sedative/Hypnotics in Adults: Miscellaneous Nonbarbiturates
  - Added that generic formulations of doxepin are available

# Sedative/Hypnotics

---

## Dosage

### *Adults (Continued)*

- Updated information about the use of benzodiazepines in geriatric patients per the 2019 American Geriatrics Society Beers Criteria
- Updated eszopiclone recommendations for patients with severe hepatic impairment
- Updated orexin receptor antagonist wording to reflect that these are no longer novel agents
- Added information about the newly approved orexin receptor antagonist Quviviq® (daridorexant)

# Sedative/Hypnotics

---

## Dosage

### *Pediatrics*

- Product labeling of flurazepam has been updated, and now states that it is not approved for pediatric use
  - Removed recommendations for usage in patients 15-17 years of age
  - Removed Table 7. Recommended Sedative/Hypnotic Dosages for Pediatric Patients: Benzodiazepines
- Removed information about parenteral barbiturate use



# Sedative/Hypnotics

---

## **Duration of Therapy**

- Updated terminology and definitions for insomnia classifications
- Updated epidemiologic information
- Updated maximum recommended treatment duration for zolpidem immediate-release and extended-release products

## **Drug-Drug Interactions**

- Reviewed and updated using Micromedex, Clinical Pharmacology, and product labeling

## **References**

- Reviewed and updated throughout the criteria set

---

# Revised Criteria: Serotonin 5-HT<sub>1B/1D</sub> Receptor Agonists

---

# Serotonin 5-HT<sub>1B/1D</sub> Receptor Agonists

---

Updated column order for all tables: Drug Name, Dosage Form/ Strength, Treatment Indication, Maximum Recommended Dosage

## **Dosage**

### *Adults*

- Table 2. Maximum Recommended Daily Adult Dosages for SRAs- Combination Therapy
  - Added generic formulation of Treximet<sup>®</sup> (sumatriptan/naproxen)

### *Pediatrics*

- Clarified that zolmitriptan nasal spray is the only formulation approved for pediatric use
- Table 3. Maximum Recommended Daily Pediatric Dosages for FDA- Approved SRAs to Manage Acute Migraine With or Without Aura- Monotherapy
  - Updated rizatriptan to reflect dosing in product labeling

# Serotonin 5-HT<sub>1B/1D</sub> Receptor Agonists

---

## **Duration of Therapy**

- Updated information to reflect that sumatriptan/naproxen combination therapy is approved to treat up to 5 migraine headaches in a 30-day period
- Table 6. Maximum Recommended SRA Adult Dosage Frequency- Monotherapy
  - Included brand names for sumatriptan intranasal spray to reduce risk of confusion
  - Updated dosing formatting for zolmitriptan intranasal for consistency
  - Removed outdated information about dosage limits for sumatriptan and zolmitriptan
  - Removed reference to Sumavel<sup>®</sup> DosePro<sup>®</sup> (sumatriptan) due to product discontinuation

# Serotonin 5-HT<sub>1B/1D</sub> Receptor Agonists

---

## **Duration of Therapy**

- Table 7. Maximum Recommended SRA Adult Dosage Frequency- Combination Therapy
  - Updated dosing formatting for sumatriptan/naproxen for consistency
- Table 8. Maximum Recommended SRA Pediatric Dosage Frequency- Monotherapy
  - Updated rizatriptan to reflect dosing in product labeling
- Table 9. Maximum Recommended SRA Pediatric Dosage Frequency- Combination Therapy
  - Updated dosing formatting for sumatriptan/naproxen for consistency

# Serotonin 5-HT<sub>1B</sub>/1D Receptor Agonists

---

## **Drug-Drug Interactions**

- Reviewed and updated using Micromedex, Clinical Pharmacology, and product labeling

## **References**

- Reviewed and updated throughout the criteria set

---

# Texas Medicaid Vendor Drug Program Drug Utilization Review Board Meeting - Retrospective Drug Use Proposals

Justin Ray Pedigo, PharmD, BCPS

---

FRIDAY, JANUARY 20, 2023

[HTTP://WWW.TXVENDORDRUG.COM/](http://www.txvendordrug.com/)